Literature DB >> 10413143

Transarterial embolization of aneurysms associated with spinal cord arteriovenous malformations. Report of four cases.

A V Konan1, J Raymond, D Roy.   

Abstract

The authors sought to show the feasibility and discuss the rationale of embolization of aneurysms associated with spinal cord arteriovenous malformations (SCAVMs). The authors reviewed the clinical presentation, magnetic resonance (MR) images, spinal angiograms, and clinical evolution of four patients treated for aneurysms associated with an SCAVM. Aneurysms were located on branches of the anterior spinal artery in three patients and on radiculopial arteries in two patients; one patient harbored two lesions. Treatment consisted of superselective bucrylate embolization of the branches harboring the aneurysms, with preservation of the arterial axis. Follow-up angiograms were obtained at 3 to 6 months postembolization in all patients. All patients presented with hemorrhagic events. Hematomyelia was clearly related to a sulcocommissural or a vasa corona aneutrysm in two patients. Another sulcocommissural aneurysm and multiple radiculopial aneurysms were presumed to be the cause of subarachnoid hemorrhage in two other patients. One patient harbored aneurysms on a sulcocommissural artery and on a radiculopial artery. All aneurysms were permanently obliterated. In one patient with a single fistula, the SCAVM was cured. The SCAVM was only partially obliterated (95, 50, and 20% in apparent volume) in three other patients. There were no complications or rebleeding episodes during a follow-up period of 17 to 37 months. Aneurysms associated with SCAVMs can be eradicated by supraselective embolization, even on the anterior spinal artery territory. For patients presenting with hemorrhage and prohibitive risk of complete resection, embolization of aneurysms may decrease the risk of further rebleeding.

Entities:  

Mesh:

Year:  1999        PMID: 10413143     DOI: 10.3171/spi.1999.90.1.0148

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

Review 1.  Endovascular treatment of spinal arteriovenous lesions: beyond the dural fistula.

Authors:  A Patsalides; J Knopman; A Santillan; A J Tsiouris; H Riina; Y P Gobin
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-22       Impact factor: 3.825

Review 2.  Subarachnoid hemorrhage following posterior spinal artery aneurysm. A case report and review of the literature.

Authors:  S Geibprasert; T Krings; J Apitzsch; M H T Reinges; K W Nolte; F J Hans
Journal:  Interv Neuroradiol       Date:  2010-07-19       Impact factor: 1.610

3.  Treatment of intramedullary arteriovenous malformations of the spinal cord.

Authors:  S Ushikoshi; K Hida; Y Kikuchi; Y Iwasaki; K Miyasaka; H Abe
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

Review 4.  Management of spinal aneurysms associated with arteriovenous malformations: systematic literature review and illustrative case.

Authors:  Bianca Baldassarre; Alberto Balestrino; Alessandro D'Andrea; Pasquale Anania; Marco Ceraudo; Monica Truffelli; Ilaria Melloni; Nicola Mavilio; Lucio Castellan; Gianluigi Zona; Pietro Fiaschi
Journal:  Eur Spine J       Date:  2021-05-27       Impact factor: 3.134

5.  The Preventive Effect of Endovascular Treatment for Recurrent Hemorrhage in Patients with Spinal Cord Arteriovenous Malformations.

Authors:  Y Niimi; H Matsukawa; N Uchiyama; A Berenstein
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-06       Impact factor: 3.825

Review 6.  Management considerations in ruptured isolated radiculopial artery aneurysms. A report of two cases and literature review.

Authors:  A C G M van Es; P A Brouwer; P W A Willems
Journal:  Interv Neuroradiol       Date:  2013-03-04       Impact factor: 1.610

7.  Spontaneous Cervical Intramedullary and Subarachnoid Hemorrhage due to a Sulco-Commissural Artery Aneurysm.

Authors:  E Donauer; M Aguilar Pérez; N Jangid; B Tomandl; O Ganslandt; H Henkes
Journal:  Clin Neuroradiol       Date:  2019-03-14       Impact factor: 3.649

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.